FibroGen (FGEN) provided clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from roxadustat Phase 3 program for the treatment of anemia of CKD

Go back to FibroGen (FGEN) provided clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from roxadustat Phase 3 program for the treatment of anemia of CKD

FibroGen Provides Additional Information on Roxadustat

April 6, 2021 4:01 PM EDT

Company Continues to be Confident in the Benefit / Risk Profile of Roxadustat

Company to Host Investor Call Today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time)

SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN) (the Company) today provided clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of chronic kidney disease (CKD).

As members of senior management were preparing for the upcoming FDA Advisory Committee meeting, we became aware that the primary... More